Recursion Pharmaceuticals Inc

NASDAQ:RXRXUnited States

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Contact Information

Headquarters

41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101

Phone

385-269-0203

Fax

801-581-7895

Executives

Independent Chairman of the Board

R. Martin Chavez

President, Chief Operating Officer

Tina Larson

Chief Executive Officer, Director

Christopher Gibson

Chief Financial Officer

Michael Secora

Chief Medical Officer

David Mauro